IL17A and colitis: In this in vivo model, the administration of MR120, at the same dose that was effective against subacute TNBS- and chronic DSS-induced colitis (1 mg/Kg), and of its analog MR452 showed a weak local protective effect, mitigating the oxidative action of neutrophils in the colon, feebly reducing IL-17 mRNA levels, and, only in the case of MR452, counteracting the increase in CCL20 production.